OBJECTIVE: We sought to describe stage-specific perinatal outcomes after selective laser photocoagulation of communicating vessels (SLPCV) for twin-twin transfusion syndrome. STUDY DESIGN: Patients with twin-twin transfusion syndrome underwent SLPCV preferentially using sequential vs standard laser technique. Patient characteristics and outcome data were examined by Quintero stage. RESULTS: Of 682 consecutive women studied, the Quintero stage distribution was: 114 stage I (17%), 177 stage II (26%), 328 stage III (48%), and 63 stage IV (9%). Perinatal survival of at least 1 twin did not differ according to stage (I-92%, II-93%, III-88%, IV-92%; P = .30). However, dual twin survival differed by stage (I-79%, II-76%, III-59%, IV-68%; P < .01), primarily because stage III pregnancies were associated with decreased donor twin survival (P < .01). Sequential SLPCV was associated with improved donor survival, independent of stage (odds ratio, 1.67; 95% confidence interval, 1.16-2.40; P < .01). CONCLUSION: Stage-specific perinatal outcomes after laser therapy may assist physicians in patient counseling and in planning future studies.
OBJECTIVE: We sought to describe stage-specific perinatal outcomes after selective laser photocoagulation of communicating vessels (SLPCV) for twin-twin transfusion syndrome. STUDY DESIGN:Patients with twin-twin transfusion syndrome underwent SLPCV preferentially using sequential vs standard laser technique. Patient characteristics and outcome data were examined by Quintero stage. RESULTS: Of 682 consecutive women studied, the Quintero stage distribution was: 114 stage I (17%), 177 stage II (26%), 328 stage III (48%), and 63 stage IV (9%). Perinatal survival of at least 1 twin did not differ according to stage (I-92%, II-93%, III-88%, IV-92%; P = .30). However, dual twin survival differed by stage (I-79%, II-76%, III-59%, IV-68%; P < .01), primarily because stage III pregnancies were associated with decreased donor twin survival (P < .01). Sequential SLPCV was associated with improved donor survival, independent of stage (odds ratio, 1.67; 95% confidence interval, 1.16-2.40; P < .01). CONCLUSION: Stage-specific perinatal outcomes after laser therapy may assist physicians in patient counseling and in planning future studies.
Authors: Andrew H Chon; Mary Rose Mamey; Sheree M Schrager; Douglas L Vanderbilt; Ramen H Chmait Journal: Prenat Diagn Date: 2018-01-24 Impact factor: 3.050
Authors: Jay D Pruetz; Sheree M Schrager; Tiffany V Wang; Arlyn Llanes; Ramen H Chmait; Douglas L Vanderbilt Journal: Am J Obstet Gynecol Date: 2015-05-21 Impact factor: 8.661
Authors: R Papanna; D Block-Abraham; L K Mann; I A Buhimschi; M Bebbington; E Garcia; N Kahlek; C Harman; A Johnson; A Baschat; K J Moise Journal: Ultrasound Obstet Gynecol Date: 2014-01 Impact factor: 7.299
Authors: Marjolijn S Spruijt; Ellen Tameeris; De-Peng Zhao; Johanna M Middeldorp; Monique C Haak; Dick Oepkes; Enrico Lopriore Journal: Fetal Diagn Ther Date: 2017-03-11 Impact factor: 2.587
Authors: Vidya Rajagopalan; Karam Ashouri; Arlyn Llanes; Douglas L Vanderbilt; Natasha Lepore; Stefan Bluml; Hollie A Lai; Jessica Wisnowski; Andrew H Chon; Ramen H Chmait Journal: Prenat Diagn Date: 2020-11-26 Impact factor: 3.050